D059451Chemicals & DrugsD20.215.26110200.964953Biosimilar Pharmaceuticalsplugins:TwitterTwitterprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonDejanMicicDejan Micic41.7886000000000087.598699999999993567Micic, DejanAssociate ProfessorMedicine-Gastroenterology34044720Narayanan R, Hariprasad SM, Sheth JOphthalmic surgery, lasers & imaging retinaBiosimilars for the Treatment of Retinal Diseases. Ophthalmic Surg Lasers Imaging Retina. 2021 05; 52(5):242-246.Ophthalmic Surg Lasers Imaging Retina2021-05-01T00:00:002021Biosimilars for the Treatment of Retinal Diseases.34388360Hanauer S, Liedert B, Balser S, Brockstedt E, Moschetti V, Schreiber SThe lancet. Gastroenterology & hepatologySafety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 10; 6(10):816-825.Lancet Gastroenterol Hepatol2021-08-11T00:00:002021Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.35041524Nahleh Z, Lyman GH, Schilsky RL, Peterson DE, Tagawa ST, Chavez-MacGregor M, Rumble RB, Gupta SJCO oncology practiceUse of Biosimilar Medications in Oncology. JCO Oncol Pract. 2022 Mar; 18(3):177-186.JCO Oncol Pract2022-01-18T00:00:002022Use of Biosimilar Medications in Oncology.35934770Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, Eduru SK, Buschke S, Lang B, Liesenfeld KH, Schaible J, McCabe DAmerican journal of clinical dermatologySwitching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728.Am J Clin Dermatol2022-08-07T00:00:002022Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.2.12650.042292710research area of0.9812020.14965219subject area forhttps://rubinlab.uchicago.edu/Rubin Lab Sitehttps://www.uchicagomedicine.org/conditions-services/inflammatory-bowel-diseaseInflammatory Bowel Disease CenterIBDMDMedicineUniversity of ChicagoSandeepParsadSandeep Parsad41.78927490000000-87.601250000000001125Parsad, SandeepRichardSchilskyRichard Schilsky41.78927490000000-87.601250000000002119Schilsky, RichardProfessor EmeritusDavid T.RubinDavid T. Rubin41.78927490000000-87.60125000000000256Rubin, David T.ProfessorStephenHanauerStephen B. Hanauer41.78927490000000-87.60125000000000660Hanauer, StephenEmeritus/Emerita38110655Kay J, Cross RK, Feldman SR, Park Y, Hanauer SBAdvances in therapyReview of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 Feb; 41(2):509-533.Adv Ther2023-12-19T00:00:002023Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases.true1true1ProfessorProfessortrue1Emeritus/EmeritaEmeritus/Emeritatrue1Professor EmeritusProfessor Emeritustrue1Associate ProfessorAssociate Professor